Sartorius Stedim Biotech SA (SDMHF)
195.00
0.00 (0.00%)
USD |
OTCM |
Jan 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 18.97B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -25.98% |
| Valuation | |
| PE Ratio | 122.39 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.210 |
| Price to Book Value | 4.353 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.7408 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.69 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 75.34% |
Profile
| Sartorius Stedim Biotech is a leading provider of tools for biopharmaceutical fermentation and fluid management. Parent Sartorius AG has a 74% stake in the company, with 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (41% of 2020 sales), the Americas (33%), and Asia-Pacific (26%). Sartorius Stedim Biotech employs over 10,000 people and has operations in more than 20 countries. |
| URL | https://www.sartorius.com |
| Investor Relations URL | https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Apr. 18, 2025 (est.) |
| Last Earnings Release | Oct. 17, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 02, 2024 |
Ratings
Profile
| Sartorius Stedim Biotech is a leading provider of tools for biopharmaceutical fermentation and fluid management. Parent Sartorius AG has a 74% stake in the company, with 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (41% of 2020 sales), the Americas (33%), and Asia-Pacific (26%). Sartorius Stedim Biotech employs over 10,000 people and has operations in more than 20 countries. |
| URL | https://www.sartorius.com |
| Investor Relations URL | https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Apr. 18, 2025 (est.) |
| Last Earnings Release | Oct. 17, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 02, 2024 |